Trevi Therapeutics Inc
TRVI12.100USD
+0.430+3.68%
Close 11/11, 16:00（ET）Quotes delayed by 15 min
1.47BMarket Cap
LossP/E TTM
More Details of Trevi Therapeutics Inc Company
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. It is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.
Trevi Therapeutics Inc Info
Ticker SymbolTRVI
Company nameTrevi Therapeutics Inc
IPO dateMay 07, 2019
CEOMs. Jennifer L. Good
Number of employees26
Security typeOrdinary Share
Fiscal year-endMay 07
Address195 Church St Fl 14
CityNEW HAVEN
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code06510-2009
Phone12033042499
Websitehttps://www.trevitherapeutics.com/
Ticker SymbolTRVI
IPO dateMay 07, 2019
CEOMs. Jennifer L. Good
Company Executives of Trevi Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. David P. Meeker, M.D.
Dr. David P. Meeker, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
352.49K
--
Dr. Thomas R. Sciascia, M.D.
Dr. Thomas R. Sciascia, M.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
214.43K
--
Ms. Jennifer L. Good
Ms. Jennifer L. Good
President, Chief Executive Officer, Interim Chief Financial Officer, Director
President, Chief Executive Officer, Interim Chief Financial Officer, Director
213.31K
--
Dr. Farrell Simon, Pharm.D.
Dr. Farrell Simon, Pharm.D.
Chief Commercial Officer
Chief Commercial Officer
76.90K
+68.46%
Ms. Anne M. Vanlent
Ms. Anne M. Vanlent
Independent Director
Independent Director
25.98K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Independent Director
Independent Director
6.35K
--
Dr. James V. (Jim) Cassella, Ph.D.
Dr. James V. (Jim) Cassella, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. Dominick C. Colangelo
Mr. Dominick C. Colangelo
Independent Director
Independent Director
--
--
Mr. Edward T. Mathers
Mr. Edward T. Mathers
Independent Director
Independent Director
--
--
Jonathan Carlson
Jonathan Carlson
IR Contact Officer
IR Contact Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. David P. Meeker, M.D.
Dr. David P. Meeker, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
352.49K
--
Dr. Thomas R. Sciascia, M.D.
Dr. Thomas R. Sciascia, M.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
214.43K
--
Ms. Jennifer L. Good
Ms. Jennifer L. Good
President, Chief Executive Officer, Interim Chief Financial Officer, Director
President, Chief Executive Officer, Interim Chief Financial Officer, Director
213.31K
--
Dr. Farrell Simon, Pharm.D.
Dr. Farrell Simon, Pharm.D.
Chief Commercial Officer
Chief Commercial Officer
76.90K
+68.46%
Ms. Anne M. Vanlent
Ms. Anne M. Vanlent
Independent Director
Independent Director
25.98K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Independent Director
Independent Director
6.35K
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
New Enterprise Associates (NEA)
9.34%
Frazier Life Sciences Management, L.P.
8.42%
Rubric Capital Management LP
7.01%
The Vanguard Group, Inc.
4.77%
BlackRock Institutional Trust Company, N.A.
4.64%
Other
65.82%
Shareholders
Shareholders
Proportion
New Enterprise Associates (NEA)
9.34%
Frazier Life Sciences Management, L.P.
8.42%
Rubric Capital Management LP
7.01%
The Vanguard Group, Inc.
4.77%
BlackRock Institutional Trust Company, N.A.
4.64%
Other
65.82%
Shareholder Types
Shareholders
Proportion
Hedge Fund
25.75%
Investment Advisor
23.38%
Investment Advisor/Hedge Fund
17.39%
Venture Capital
14.71%
Private Equity
11.14%
Research Firm
2.32%
Individual Investor
0.80%
Pension Fund
0.35%
Bank and Trust
0.12%
Other
4.03%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
272
116.14M
95.37%
+14.43M
2025Q2
232
94.28M
77.42%
+5.93M
2025Q1
226
89.66M
76.74%
+2.50M
2024Q4
177
80.67M
91.74%
+11.34M
2024Q3
156
59.14M
78.18%
-6.31M
2024Q2
148
56.93M
80.80%
-4.85M
2024Q1
147
52.57M
76.38%
-8.69M
2023Q4
131
54.54M
85.48%
-544.63K
2023Q3
124
54.64M
88.55%
-1.52M
2023Q2
115
54.75M
93.54%
+3.66M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
New Enterprise Associates (NEA)
11.37M
9.34%
-1.85M
-14.01%
Aug 11, 2025
Frazier Life Sciences Management, L.P.
10.26M
8.42%
--
--
Jun 30, 2025
Rubric Capital Management LP
8.53M
7.01%
+3.99M
+87.99%
Jun 30, 2025
The Vanguard Group, Inc.
5.32M
4.37%
+1.48M
+38.53%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.65M
4.64%
+1.10M
+24.11%
Jun 30, 2025
Vivo Capital, LLC
4.49M
3.69%
+1.00M
+28.67%
Jun 30, 2025
AllianceBernstein L.P.
4.28M
3.52%
+4.26M
+19064.53%
Jun 30, 2025
Woodline Partners LP
4.05M
3.32%
+1.99M
+96.64%
Jun 30, 2025
Invus Public Equities Advisors, LLC
3.94M
3.23%
+1.07M
+37.54%
Jun 30, 2025
Octagon Capital Advisors LP
3.67M
3.02%
+350.00K
+10.54%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
SPDR S&P Pharmaceuticals ETF
1.38%
Invesco Dorsey Wright Healthcare Momentum ETF
1.1%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.03%
ALPS Medical Breakthroughs ETF
0.66%
Invesco Dorsey Wright SmallCap Momentum ETF
0.42%
Optimize Strategy Index ETF
0.29%
Vanguard US Momentum Factor ETF
0.21%
iShares Micro-Cap ETF
0.15%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.11%
View more
SPDR S&P Pharmaceuticals ETF
Proportion1.38%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion1.1%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.03%
ALPS Medical Breakthroughs ETF
Proportion0.66%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.42%
Optimize Strategy Index ETF
Proportion0.29%
Vanguard US Momentum Factor ETF
Proportion0.21%
iShares Micro-Cap ETF
Proportion0.15%
ProShares Ultra Nasdaq Biotechnology
Proportion0.12%
Invesco Nasdaq Biotechnology ETF
Proportion0.11%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
